Exploring Innovations in Copper-based Diagnostics for Neuroendocrine Tumors
Revolutionizing Cancer Detection with Copper-based Diagnostics
NUCLIDIUM AG, a pioneering radiopharmaceutical company based in Switzerland and Germany, is making remarkable strides in the fight against cancer. By utilizing a unique copper-based theranostic platform, they are developing innovative solutions for the diagnosis and treatment of neuroendocrine tumors. During the upcoming European Association of Nuclear Medicine (EANM) congress, scheduled for October 2025, NUCLIDIUM’s research will take center stage, showcasing its latest clinical data derived from a Phase I/II study.
First Clinical Data Presentation at EANM 2025
The excitement is palpable as NUCLIDIUM prepares to unveil preliminary results from their ongoing clinical trial. The abstract focused on the company's PET tracer, [61Cu]Cu-NODAGA-LM3, is set to be shared during a prestigious oral presentation at EANM 2025. This particular tracer is being evaluated for its efficacy in detecting SSTR-positive gastroenteropancreatic and bronchopulmonary neuroendocrine tumors (GEP & BP-NETS). This is a significant step towards improving diagnosis and treatment pathways for patients suffering from these challenging conditions.
Details of the Oral Presentation
Scheduled for Monday, October 6, 2025, at 9:45 AM CEST, the oral presentation will occur in the Clinical Oncology Track. The session carries the weight of being recognized as a Top Rated Oral Presentation by the Oncology & Theranostics Committee under the NET Imaging theme. Dr. Guillaume Nicolas, the principal investigator and Deputy Head of Nuclear Medicine at the University Hospital Basel, will present the compelling findings from the trial.
Abstract Information
The title of the abstract, “A phase I/II study of [61Cu]Cu-NODAGA-LM3 for the detection of neuroendocrine tumours: Preliminary results of the COPPER PET in NET Trial,” signifies the critical nature of this research. The insights gained from this study are expected to set a new benchmark in the diagnosis of neuroendocrine tumors, facilitating early detection and appropriate therapeutic interventions.
About NUCLIDIUM and its Vision
NUCLIDIUM is not just advancing diagnostics; it aims to transform cancer treatment altogether. This clinical-stage biotechnology company leverages copper isotopes, specifically Copper-61 for diagnostic purposes and Copper-67 for therapeutic applications. By creating a radiopharmaceutical platform capable of overcoming existing limitations, NUCLIDIUM stands at the forefront of innovation in the field.
The company’s dual facilities in Switzerland and Germany bring together cutting-edge chemistry, extensive clinical knowledge, and strategic manufacturing capabilities. This solid foundation enables them to deliver scalable and clinically effective theranostic solutions that address significant medical needs within oncology and women's health.
Commitment to Patient Welfare
In its mission to enhance the reach and effectiveness of radiotheranostics, NUCLIDIUM is dedicated to tackling unmet medical challenges. This commitment is reflected not only in their innovative research but also in the ethical responsibility to ensure that their advancements are accessible to patients worldwide.
Contact Information for Inquiries
If you have questions or require more information, please feel free to reach out:
NUCLIDIUM AG
Leila Jaafar, PhD, CEO
Email: info@nuclidium.com
For Media and Investor Relations
Trophic Communications
Stephanie May
Email: nuclidium@trophic.eu
Phone: +49 171 1855682
Frequently Asked Questions
What is NUCLIDIUM focusing on at EANM 2025?
NUCLIDIUM will present clinical data from its Phase I/II study on a copper-based PET tracer for neuroendocrine tumors.
Who is presenting the data at the congress?
Dr. Guillaume Nicolas, the Deputy Head of Nuclear Medicine at the University Hospital Basel, will present the findings.
What is the significance of the copper-based PET tracer?
This tracer aids in detecting neuroendocrine tumors, potentially improving diagnosis and treatment efficacy.
What are the goals of NUCLIDIUM's research?
NUCLIDIUM aims to enhance diagnosis and treatment for patients with cancer through innovative radiopharmaceuticals.
How can one contact NUCLIDIUM for more information?
For inquiries, reach out to Leila Jaafar, CEO, via email at info@nuclidium.com.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
